Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD, on B-Cell NHL and CLL: Clinical Trial Results on T-Cell Therapy

2015 ASH Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Cameron J. Turtle, MBBS, PhD, of the Fred Hutchinson Cancer Research Center, discuss anti-CD19 chimeric antigen receptor-modified T-cell therapy and clinical outcome (Abstract 184).

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remiss...

Symptom Management

David Henry, MD

David Henry, MD, on Anticoagulants: Expert Perspective

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Symptom Management

Alok A. Khorana, MD

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 42...

Leukemia

Julie Vose, MD, MBA

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia ...

Lymphoma

Jonathon B. Cohen, MD

Jonathon Cohen, MD, on Deferring MCL Treatment

Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in ...

Apr

Today In Oncology

Julie Vose, MD, MBA, and Cameron J. Turtle, MBBS, PhD, on B-Cell NHL and CLL: Clinical Trial Results on T-Cell Therapy

Related Videos

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

David Henry, MD, on Anticoagulants: Expert Perspective

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Jonathon Cohen, MD, on Deferring MCL Treatment

Chemotherapy-Induced Dormancy in AML Allows Cancer Cell Survival, May Contribute to Relapse

FDA Approves New Indication for Daunorubicin/Cytarabine Secondary Acute Myeloid Leukemia in Pediatric Patients

Study Identifies Factors That May Lower the Risk of CNS Relapse in Pediatric Patients With ALL

RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML

Recent Studies Explore Efficacy of COVID-19 Vaccination in Patients With Leukemia and Myeloma